Company / Cost of Revenue
Lexaria Bioscience Corp. Cost of Revenue History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$4.8K
FY2025
5-year range
$4.8K / $175.3K
FY2021-FY2025
Trend
-84.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 3 consecutive years, from $175,346 in FY2022 to $4,822 in FY2025.
Based on SEC 10-K filings.
$4,822 in FY2025 with a 5-year CAGR of -26.8%.
Improved from $71,841 to $4,822 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -69.8%
- 5-Year CAGR
- -26.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Lexaria Bioscience Corp.'s cost of revenue has declined for 3 consecutive years.
- 5-year CAGR of -26.8%, indicating a declining trend.
- In FY2025, cost of revenue decreased 84.7% year-over-year.
- Peak cost of revenue was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.8K | -84.7% |
| FY2024 | $31.5K | -56.2% |
| FY2023 | $71.8K | -59.0% |
| FY2022 | $175.3K | +76.4% |
| FY2021 | $99.4K | +334.1% |
| FY2020 | $22.9K | -9.1% |
| FY2019 | $25.2K | -44.8% |
| FY2017 | $45.6K | +52.6% |
| FY2016 | $29.9K | - |
| FY2015 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026